Cookie Policy

Manage your cookies preferences by toggling this button

Health

Pharmacodiversity Oriented Synthesis: A New Tool For The Rapid Discovery Of Treatment For Multidrug-Resistant Bacteria

Andrew Christopher silvanus

Nationality British

Year of selection 2010

Institution UVSQ

Country France

Risk Health

Post-Doctoral Fellowship

1 year

60000 €

Antibiotic Resistance: Finding New Drugs Faster

The threat posed by drug-resistant bacteria and other microbes is increasing as new strains emerge. Yet, major pharmaceutical companies are not seeking new drugs to fight back. Dr. Andrew Silvanus is developing a faster, easier method of screening candidates for potential new “superdrugs”: starting with natural substances containing molecular structures already known to fight infection, tweaking them in a variety of ways, and testing the results. Silvanus's work has the potential to accelerate vital antibiotic discovery.

To add or modify information on this page, please contact us at the following address: community.research@axa.com